Balaxi Pharmaceuticals Q2 FY27: revenue up 44.8% to ₹81 Cr, net profit up 450.0% to ₹1 Cr
Results · 12 Nov 2026 · Balaxi Pharmaceuticals (BALAXI)
| Q2 FY27 | ₹ Cr | YoY |
|---|---|---|
| Revenue | 81 | +44.8% |
| Operating profit | 5 | +325.0% |
| Net profit | 1 | +450.0% |
Balaxi Pharmaceuticals reported Q2 FY27 consolidated revenue from operations of Rs 81.37 crore, up 44.85% YoY, with EBITDA of Rs 5.12 crore, up 338.19%, and PAT of Rs 1.15 crore, up 450.29%, for the quarter ended September 30, 2026.
H1 FY27 revenue rose 27.68% YoY to Rs 162.05 crore with PAT up 390.30% to Rs 2.45 crore, and the company added 31 new product registrations while its Jadcherla oral solid dosage facility became operational.
Operating margin was 6.3%, up 4.1 pp on a year earlier and up 0.4 pp on the quarter before.
NSE filing (PDF) · Company page · Results tracker
Anand Ganapathy K | SEBI Registered Research Analyst | INH000016630.